These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8502827)

  • 1. Long-term toxicity and economic aspects: critical review.
    Brunner KW
    Recent Results Cancer Res; 1993; 127():285-7. PubMed ID: 8502827
    [No Abstract]   [Full Text] [Related]  

  • 2. How much will Herceptin really cost?
    Barrett A; Roques T; Small M; Smith RD
    BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant trastuzumab for breast cancer: an increasingly common ethical and economic conundrum.
    Grove ML
    BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293847
    [No Abstract]   [Full Text] [Related]  

  • 4. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
    Hillner BE; Smith TJ
    J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
    [No Abstract]   [Full Text] [Related]  

  • 5. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.
    Chen W; Jiang Z; Shao Z; Sun Q; Shen K
    Value Health; 2009; 12 Suppl 3():S82-4. PubMed ID: 20586989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant anthracyclines and taxanes: quantifying the costs of therapeutic advances in breast cancer.
    Morris PG; Bach PB
    Onkologie; 2009 Sep; 32(8-9):464-6. PubMed ID: 19745589
    [No Abstract]   [Full Text] [Related]  

  • 7. Doctors less likely than patients to report toxicity of cancer treatments, study shows.
    Mayor S
    BMJ; 2015 Jan; 350():h485. PubMed ID: 25630342
    [No Abstract]   [Full Text] [Related]  

  • 8. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
    Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
    Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefit of the 21-gene breast cancer recurrence score assay for patients in Singapore.
    de Lima Lopes G; Chien R; Hornberger J
    Breast J; 2013; 19(2):220-1. PubMed ID: 23320386
    [No Abstract]   [Full Text] [Related]  

  • 10. Side effects of adjuvant treatment of breast cancer.
    Shapiro CL; Recht A
    N Engl J Med; 2001 Jun; 344(26):1997-2008. PubMed ID: 11430330
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-utility analysis of adjuvant therapies for breast cancer in Iran.
    Bastani P; Kiadaliri AA
    Int J Technol Assess Health Care; 2012 Apr; 28(2):110-4. PubMed ID: 22559752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.
    Desch CE; Hillner BE; Smith TJ; Retchin SM
    J Clin Oncol; 1993 Apr; 11(4):777-82. PubMed ID: 8478671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer.
    Chen E; Tong KB; Malin JL
    Am J Manag Care; 2010 Dec; 16(12):e333-42. PubMed ID: 21291290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel C; Rayson D; Younis T
    Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain metastases in HER2-positive breast cancer.
    Lin NU
    Lancet Oncol; 2013 Mar; 14(3):185-6. PubMed ID: 23414590
    [No Abstract]   [Full Text] [Related]  

  • 16. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan.
    Lang HC; Chen HW; Chiou TJ; Chan AL
    J Med Econ; 2016 Oct; 19(10):923-7. PubMed ID: 27135256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
    Skedgel C; Rayson D; Dewar R; Younis T
    Breast Cancer Res Treat; 2007 Mar; 101(3):325-33. PubMed ID: 16897433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
    Jacobs VR; Kates RE; Kantelhardt E; Vetter M; Wuerstlein R; Fischer T; Schmitt M; Jaenicke F; Untch M; Thomssen C; Harbeck N
    Breast Cancer Res Treat; 2013 Apr; 138(3):839-50. PubMed ID: 23568480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to P. Baldo et al.
    Perrone F; Di Maio M; Gallo C
    J Clin Oncol; 2015 Sep; 33(25):2826. PubMed ID: 26195706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.